(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of your Favored kind of footwear - 2When does Spotify Wrapped come out? The music streamer says 'soon.'
- 3Norovirus is spreading earlier again this year, wastewater data shows
- 4Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- 5Favored Vehicle for Seniors: Make Your Determination
- Audits of Espresso Types: Which Mix Is for You?
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
- Top 15 Style Creators Changing the Business
- When darkness shines: How dark stars could illuminate the early universe
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
